ASH Press Briefing 1, Saturday December 9, 2023
Die Videoaufzeichnungen der vorgestellten Abstracts werden nach der Aufhebung des Embargos am 10.12. ab 18 Uhr publiziert.
- LBA-1 Tafasitamab Plus Lenalidomide and Rituximab for RR Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
- LBA-4 Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
- LBA-5 Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
- LBA-6 Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial